Trial Profile
Phase 1b/2 Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Everolimus (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer; Brain metastases; Male breast cancer
- Focus Therapeutic Use
- 08 Nov 2019 Status changed from active, no longer recruiting to completed.
- 07 Aug 2018 Planned End Date changed from 28 Jun 2019 to 28 Jun 2020.
- 07 Aug 2018 Planned primary completion date changed from 28 Jun 2018 to 28 Jun 2019.